| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 17,110,425 | 14,745,702 | 13,712,528 | 12,411,048 |
| Cost of goods sold | 14,507,807 | 13,581,888 | 11,662,729 | 11,204,186 |
| Gross profit | 2,602,618 | 1,163,814 | 2,049,799 | 1,206,862 |
| General and administrative expenses | 2,040,341 | 1,490,485 | 1,478,702 | 1,782,957 |
| Salaries and wages | 1,919,950 | 1,868,443 | 1,040,019 | 1,317,782 |
| Sales and marketing expenses | 64,794 | 21,706 | 28,155 | 41,848 |
| Research and development costs | 18,337 | 74,637 | 15,629 | - |
| Depreciation and amortization expense | 377,911 | 353,862 | 320,439 | 304,139 |
| Total operating expenses | 4,421,333 | 3,809,133 | 2,882,944 | 3,446,726 |
| Loss from operations | -1,818,715 | -2,645,319 | -833,145 | -2,239,864 |
| Foreign currency transaction, net | - | - | 175,824 | 139,016 |
| Other income (expense), net | -5,577 | -42,190 | -68,137 | -1,921 |
| Interest expense | 669,150 | 388,814 | 187,107 | 181,429 |
| Gain on equity investments, net | - | 2,639 | - | 428 |
| Interest income | 100,698 | 105,787 | 91,326 | 101,236 |
| Gain on equity investments, net | 2,998 | - | - | - |
| Non-cash interest expense | 201,447 | 163,103 | - | - |
| Change in fair value of derivative liability | -311,778 | - | - | - |
| Foreign currency transaction, net | - | 442,524 | - | - |
| Gain on digital assets | 57 | - | - | - |
| Change in fair value of convertible notes | -2,178,039 | -139,592 | - | - |
| Gain on equity investments, net | - | - | 3,142 | - |
| Foreign currency transaction, net | -271,937 | - | - | - |
| Total other income (expense), net | -3,534,175 | -182,749 | 15,048 | 57,330 |
| Loss before income taxes | -5,352,890 | -2,828,068 | -818,097 | -2,182,534 |
| Income tax expense | 0 | 0 | - | - |
| Net loss | -5,352,890 | -2,828,068 | - | - |
| Deemed dividend on issuance of warrants | 0 | - | - | - |
| Deemed dividend on warrant exchange/modification | 0 | - | - | - |
| Net loss attributable to common stockholders | -5,352,890 | -2,828,068 | -818,097 | -2,182,534 |
| Deemed dividend on warrant exchangemodification | - | - | - | -9,793 |
| Deemed dividend | - | - | - | 6,185,231 |
| Net loss attributable to common stockholders | - | - | -818,097 | -8,377,558 |
| Foreign currency translation adjustment, net | 255,263 | 1,562,470 | 1,031,268 | 747,879 |
| Total comprehensive loss | -5,097,627 | -1,265,598 | 213,171 | -7,629,679 |
| Basic | 30,625,284 | 28,753,492 | 26,037,608 | 18,418,287 |
| Basic net loss per share | -0.17 | -0.1 | -0.03 | -0.45 |
| Diluted | 30,625,284 | 28,753,492 | 26,037,608 | 18,418,287 |
| Diluted net loss per share | -0.17 | -0.1 | -0.03 | -0.45 |
Cosmos Health Inc. (COSM)
Cosmos Health Inc. (COSM)